Is PNU 155971 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use PNU 155971? Is PNU 155971 safe for nursing mother and child? Does PNU 155971 extracts into breast milk? Does PNU 155971 has any long term or short term side effects on infants? Can PNU 155971 influence milk supply or can PNU 155971 decrease milk supply in lactating mothers?
PNU 155971 lactation summary
- DrLact safety Score for PNU 155971 is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of PNU 155971 may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that PNU 155971 may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using PNU 155971 .
- Usage of PNU 155971 is in contradiction to breastfeeding hence if it is must to use PNU 155971 and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About PNU 155971 usage in lactation
Steroidal aromatase inhibitor. Using this drug while breastfeeding in not recommended
Answer by DrLact: About PNU 155971 usage in lactation
No information is available on the use of PNU 155971 during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during PNU 155971 therapy and for 1 month after the last dose.
Alternate Drugs
Carboplatin(Dangerous)
Hydroxyurea(Low Risk)
Gemcitabine(Dangerous)
Paclitaxel(Dangerous)
Etoposide(Dangerous)
Fluorouracil(Dangerous)
Doxorubicin(Dangerous)
Alemtuzumab(Low Risk)
Nivolumab(Unsafe)
Cyclophosphamide(Dangerous)
Rituximab(Low Risk)
Vinblastine(Dangerous)
Cisplatin(Unsafe)
Bevacizumab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Busulfan(Dangerous)
Pazopanib(Unsafe)
Vinorelbine(Dangerous)
Trastuzumab(Unsafe)
Dacarbazine(Dangerous)
Imatinib(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Letrozole(Dangerous)
Azelaic Acid(Safe)
Erlotinib(Unsafe)
Dasatinib(Unsafe)
Exemestane(Dangerous)
Vincristine(Dangerous)
Dactinomycin(Dangerous)
Tamoxifen(Dangerous)
Nilotinib(Unsafe)
Mitoxantrone(Dangerous)
Ipilimumab(Unsafe)
Mercaptopurine(Safe)
Cetuximab(Unsafe)
Letrozole(Dangerous)
Exemestane(Dangerous)